Pfizer, Inc.

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:09 2023-12-08 pm EST			5-day change	1st Jan Change
28.78 ^USD	+0.52%		-0.45%	-43.83%

Dec. 08	Sector Update: Health Care Stocks Rise Late Afternoon	MT
Dec. 08	Sector Update: Health Care Stocks Steady in Afternoon Trading	MT

Pfizer Says Its RSV Vaccine Will Have $295 Per Dose List Price For Maternal Use

September 22, 2023 at 11:57 am EDT

Sept 22 (Reuters) - Pfizer Inc:

* PFIZER SAYS ITS RSV VACCINE WILL HAVE $295 PER DOSE LIST PRICE FOR MATERNAL USE - CDC ADVISORY PANEL MEETING

* PFIZER SAYS ITS RSV VACCINE WILL HAVE $295 PER DOSE LIST PRICE FOR MATERNAL USE Further company coverage:

Latest news about Pfizer, Inc.

Sector Update: Health Care Stocks Rise Late Afternoon	Dec. 08	MT
Sector Update: Health Care Stocks Steady in Afternoon Trading	Dec. 08	MT
Top Stories at Midday: Unemployment Rate Falls; Carrier Global Rises on Honeywell Deal; Tesla's Norway Labor Woes; FDA Approves Casgevy, Lyfgenia; Putin's 2024 Presidential Run	Dec. 08	MT
Pfizer Secures Conditional Marketing Approval from EU for Blood Cancer Therapy	Dec. 08	MT
Pfizer obtains EU marketing authorization for multiple myeloma	Dec. 08	CF
Pfizer's Multiple Myeloma Drug Elrexfio Receives Conditional Marketing Approval From European Commission	Dec. 08	MT
Pfizer Gets Europe OK for Elrexfio in Multiple Myeloma	Dec. 08	DJ
European Commission Approves Pfizer's ELREXFIO for Relapsed and Refractory Multiple Myeloma	Dec. 08	CI
US Equity Markets Close Higher Thursday Following Jobless Claims, Wholesale Inventories Data	Dec. 07	MT
AbbVie's $8.7 bln bet on Cerevel is risky but smart, analysts say	Dec. 07	RE
Bain scores over tenfold return with $8.7 billion Cerevel sale	Dec. 07	RE
US sets policy to seize patents of government-funded drugs if price deemed too high	Dec. 07	RE
Top Stories at Midday: Moody's Downgrades Chinese Banks; AbbVie Acquires Cerevel; Washington to Use March-In Law to Seize Pharma Patents; JetBlue Hikes Outlook	Dec. 07	MT
Biden Administration Launches Measures to Cut Health Care Costs; Proposes Use of 'March-In Rights' for Drugs	Dec. 07	MT
President Biden Announces Health Care Measure to Lower Costs, Promote Competition, 'March-In' Drug Patents on Govt-Funded Research	Dec. 07	MT
US sets policy to seize government-funded drug patents if price deemed too high	Dec. 07	RE
Lifeon Pharmaceutical Gets Chinese Drug Regulator's Nod to Market Doxazosin Mesylate	Dec. 07	MT
AbbVie to buy drug developer Cerevel for $8.7 billion	Dec. 06	RE
Pfizer: 'encouraging' data in breast cancer	Dec. 06	CF
Health Canada authorizes Novavax's updated COVID shot for Omicron	Dec. 05	RE
Arvinas, Pfizer Report Clinical Data for Vepdegestrant Combined With Palbociclib in Breast Cancer Treatment	Dec. 05	MT
Arvinas, Inc. and Pfizer Inc. Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®?) and Plans to Expand Vepdegestrant Development Program	Dec. 05	CI
Altimmune open to partnerships, deals with drugmakers, says CEO	Dec. 05	RE
Pfizer: recruitment completed for VALOR trial	Dec. 05	CF
BridgeBio Seeks FDA Approval of Acoramidis in Transthyretin Amyloid Cardiomyopathy	Dec. 05	DJ

Pfizer, Inc. the world's leading pharmaceutical group. Net sales break down by family of products as follows: - vaccines (52.4%); - drugs for the treatment of cancer (15.2%); - cardiovascular, metabolic and analgesic drugs (11.5%); - injectable, anti-infectives drugs and active pharmaceutical ingredients (9%); - drugs for inflammatory and immune diseases (5.5%); - drugs for rare diseases (4.4%); - other (2%). At the end of 2021, the group had more than 39 production sites worldwide. Net sales are distributed geographically as follows: the United States (36.6%), Europe (22.6%) and other (40.8%).

Sector

Pharmaceuticals

Calendar

2023-12-11 - American Society of Hematology Meeting - Abstract Number -1057

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs

October 31, 2023 at 04:50 pm EDT

More Strategies

Ratings for Pfizer, Inc.

Trading Rating :

Investor Rating :

ESG Refinitiv :

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

28.78USD

Average target price

40.41USD

Spread / Average Target

+40.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PFIZER, INC.	-43.83%	163 B $
ELI LILLY AND COMPANY	+63.47%	538 B $
NOVO NORDISK A/S	+42.56%	430 B $
JOHNSON & JOHNSON	-12.58%	372 B $
ABBVIE INC.	-7.63%	264 B $
MERCK & CO., INC.	-6.49%	263 B $
ROCHE HOLDING AG	-12.81%	232 B $
NOVARTIS AG	+1.35%	198 B $
ASTRAZENECA PLC	-9.77%	197 B $
AMGEN INC.	+2.47%	144 B $